BioWorld Asia

March 30, 2011

View Archived Issues

Anergis Picks up $19.6M in First VC Round Since Founding

Study: Glucose Metabolism Control Includes Micro-RNAs

Proximagen Sees Potential for Failed Migraine Drug in Epilepsy

Seek, Pernix Hire J.P. Morgan to Sell Cough Drug Candidate

FDA to Silence 'Noise' from too Many Adverse Events

Other News To Note

Actelion Fends Off Activist's Board Overhaul Proposal

LONDON – Actelion SA reinforced its defenses against the unwanted attention of activist investor Elliott Advisors, which is seeking to replace the company's board with six of its own nominees. (BioWorld International) Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...